BackBB Biotech AG Overview

BB Biotech AG Receivables

BB Biotech AG's receivables is $13M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$13.22M

Peer trimmed avg / median

Loading

BB Biotech AG Receivables History

Loading

BB Biotech AG vs. peers: Receivables Comparison

Loading

BB Biotech AG Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

BB Biotech AG (BBZA.DE) FAQ

The latest receivables for BBZA.DE is $13M as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside BB Biotech AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, BBZA.DE's receivables moved from $0 to $13M. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BB Biotech AG's operating scale or balance-sheet position.

A receivables figure of $13M for BBZA.DE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BBZA.DE's receivables ($13M), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.